A practical reference on WADA Prohibited List: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-16. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Selenium forms several allotropes that interconvert with temperature changes, depending somewhat on the rate of temperature change. When prepared in chemical reactions, selenium is usually an amorphous, brick-red powder. When rapidly melted, it forms the black, vitreous form, usually sold commercially as beads. The structure of black selenium is irregular and complex and consists of polymeric rings with up to 1000 atoms per ring. Black selenium is a brittle, lustrous solid that is slightly soluble in CS2. Upon heating, it softens at 50 °C and converts to gray selenium at 180 °C; the transformation temperature is reduced by presence of halogens and amines. The red α, β, and γ forms are produced from solutions of black selenium by varying the evaporation rate of the solvent (usually CS2). They all have a relatively low, monoclinic crystal symmetry (space group 14) and contain nearly identical puckered cyclooctaselenium (Se8) rings as in sulfur. The eight atoms of a ring are not equivalent (i.e. they are not mapped one onto another by any symmetry operation), and in fact in the γ-monoclinic form, half the rings are in one configuration (and its mirror image) and half in another. The packing is most dense in the α form. In the Se8 rings, the Se–Se distance varies depending on where the pair of atoms is in the ring, but the average is 233.5 pm, and the Se–Se–Se angle is on average 105.7°. Other selenium allotropes may contain Se6 or Se7 rings.
While it has been shown that the ACD when performing the catalysis uses magnesium and ATP for the formation of the cross-links the specifics of the mechanism are uncertain. Though an interesting aspect of the cross-link formed in this case, is that it uses a non-terminal Glu to ligate to a non-terminal Lys, which seems to be rare in the process of forming an isopeptide bond. Though the chemistry of ACD is still to be resolved, it shows that isopeptide bond formation is not dependent simply on Asp/Asn for non-terminal isopeptide linkages between proteins. The final case to be looked is the curious case of the post translational modifications of microtubilin (MT). MT contains a wide array of post translational modifications; however the two of most regarded interest are polyglutamylation and polyglycylation. Both modifications are similar in the sense they are repeating stretches of the same amino acid fused to the side chain carboxyl group of glutamate at the c-terminal region of the MT. The enzymatic mechanisms are not fully fleshed out as not much is known about the polyglycating enzyme. In the case of polyglutamylation the exact mechanism is also unknown, but it does seem to be ATP-dependent. Though again there is a lack of clarity in regard to the enzymatic chemistry, there is still valuable insight in the formation of isopeptide bonds using the R-group carboxyl of Glu in conjunction with the N-terminal amino of the modifying peptides.
The endothoracic fascia is the layer of loose connective tissue deep to the intercostal spaces and ribs, separating these structures from the underlying pleura. This fascial layer is the outermost membrane of the thoracic cavity. The endothoracic fascia contains variable amounts of fat. It becomes more fibrous over the apices of the lungs as the suprapleural membrane. It separates the internal thoracic artery from the parietal pleura.
Sources: en.wikipedia.org
About 3 or 4 o'clock in the morning we were seized with an extraordinary weakness in all our limbs attended with a numbness or sensation like to that caused by exposeing [sic] ones hands or feet to a fire after having been pinched by frost. I had almost lost the sence [sic] of feeling nor could I distinguish between light and heavy bodies, a quart pot full of water and a feather was the same in my hand. If the patient survives 24 hours, recovery without any after effects will usually occur over a few days. Therapy is supportive and based on symptoms, with aggressive early airway management. If consumed, treatment can consist of emptying the stomach, feeding the victim activated charcoal to bind the toxin, and taking standard life-support measures to keep the victim alive until the effect of the poison has worn off. Alpha adrenergic agonists are recommended in addition to intravenous fluids to increase the blood pressure; anticholinesterase agents "have been proposed as a treatment option but have not been tested adequately". No antidote has been developed and approved for human use, but a primary research report (preliminary result) indicates that a monoclonal antibody specific to tetrodotoxin is in development by USAMRIID that was effective, in the one study, for reducing toxin lethality in tests on mice.
=== Nitrogen-based crude protein === The classic assays for protein concentration in food are the Kjeldahl method and the Dumas method. These tests determine the total nitrogen in a sample. The only major component of most food which contains nitrogen is protein (fat, carbohydrate and dietary fiber do not contain nitrogen). If the amount of nitrogen is multiplied by a factor depending on the kinds of protein expected in the food the total protein can be determined. This value is known as the "crude protein" content. The use of correct conversion factors is heavily debated, specifically with the introduction of more plant-derived protein products. However, on food labels the protein is calculated as the amount of nitrogen multiplied by 6.25, because the average nitrogen content of proteins is about 16%. The Kjeldahl test is typically used, because it is the method the AOAC International has adopted and is therefore used by many food standards agencies around the world, though the Dumas method is also approved by some standards organizations. Nitrogen-based protein measurement cannot distinguish between true protein and non-protein nitrogen (NPN). NPN occurs in significant amounts in milk, edible insects, and fish. In addition, accidental contamination and intentional adulteration of protein meals with NPN sources that inflate crude protein content measurements have been known to occur in the food industry for decades.
. These differential equations are the analogues for deformable materials to Newton's equations of motion for particles – the Navier–Stokes equations describe changes in momentum (force) in response to pressure
Having "engaged in practices that exposed players to significant risks to their health and safety as well as the risk of using substances that were prohibited by the AFL Anti-Doping Code and the World Anti-Doping Code". Allowing "a culture of frequent, uninformed and unregulated use of the injection of supplements" at the club. Had "failed to meaningfully inform players of the substances the subject of the program and obtain their informed consent to the administration of the substances". Having an incomplete record-keeping system made it impossible to determine with certainty whether or not players had been administered banned supplements. The bypassing of human resources practices relating specifically to the employment of Robinson and Dank. The interim report found that Essendon had intended the program to be an innovative program of unprecedented scale to deliver a competitive edge to the club, but that it had not done adequate research nor established clear lines of accountability for those implementing the program. The AFL Tribunal later commented that there was a "deplorable absence of records in the program relating to its administration." Essendon and the AFL discussed and negotiated penalties for the charges over two days in August. On 27 August 2013, five days before the final round of the 2013 home-and-away season, the following penalties were agreed to and imposed:
Sources: en.wikipedia.org
== Career and research == After a postdoctoral training fellowship at the University of Bristol, Robinson took up a junior position in the mass spectrometry unit at the University of Oxford, where she began analysing protein folding. Robinson and colleagues successfully captured protein folding in the presence of the chaperone GroEL, demonstrating that at least some aspects of protein secondary structure could be studied in the gas phase. Robinson was the first woman professor in the department of chemistry at both the University of Cambridge (2001) and the University of Oxford (2009). Her research demonstrated that electrospray ionization mass spectrometry could be used to study proteins and other complex macromolecules in the gas phase. In addition to her contributions to the study of protein folding, Robinson has studied ribosomes, molecular chaperones and most recently membrane proteins. Her research has made contributions to gas-phase structural biology, including the study of protein complexes in their native environments for drug discovery. Additionally, she is a co-founder of OMass Therapeutics, a University of Oxford spin-out company applying mass spectrometry technology to drug discovery.
=== Sodium channels === AM404 has also been reported to inhibit voltage-gated sodium channels in the peripheral nervous system, with much greater potency than its effects at previously proposed targets. Specifically, it inhibits Nav1.8 and 1.7 channels at nanomolar concentrations in vitro. AM404 injected into the hind paw of rats increase the pain threshold for the treated paw, but not the untreated paw, confirming the peripheral nature of this effect. It also lowers pain responses in a few other in vivo models when injected directly into the affected area. Other tested metabolites of paracetamol do not block pain-sensing sodium channels in vitro.
Agribusiness Arla Foods (dairy) Dansk Landbrugs Grovvareselskab (DLG) (agricultural coop (Danish a.m.b.a.). Main focus is agricultural supply and trade) Danish Crown (meat products) Banking Danske Bank (commercial banking and mortgage lending) Nordea Nykredit Jyske Bank Saxo Bank Sydbank Clothing and attire ECCO (shoe and leather accessories manufacturer and retailer) Bestseller Construction FLSmidth (global supplier of equipment and services to the cement and minerals industries) Rockwool (mineral wool producer with production in 28 countries) Velux (windows and skylights production, owned by Villum Foundation) Rambøll COWI Energy technology Vestas (wind turbines) Siemens Wind Power (wind turbines) Danfoss (climate and energy) Grundfos (the world's largest pump manufacturer) NKT A/S (Power cables and subsea umbilicals) Ørsted (company) (Formerly known as DONG energy) Electronics Linak Bang and Olufsen (hi-fi equipment) Nilfisk Ortofon Danfoss Food and drink Carlsberg (brewing company) Royal Unibrew Novonesis (food ingredients and enzymes) Danisco (enzymes, biotechnology and pharmaceutical supplier) Insurance Alm. Brand Tryg Medical equipment Widex William Demant Pharmaceutical and biotechnology Many of the largest food producers are also engaged in biotechnology and research. Notable companies dedicated to the pharmaceutical and biotechnology sector, includes:
==== Antimicrobial ==== Introduction of silver into bacterial cells induces a high degree of structural and morphological changes, which can lead to cell death. As the silver nanoparticles come in contact with the bacteria, they adhere to the cell wall and cell membrane. Once bound, some of the silver passes through to the inside, and interacts with phosphate-containing compounds like DNA and RNA, while another portion adheres to the sulfur-containing proteins on the membrane. The silver-sulfur interactions at the membrane cause the cell wall to undergo structural changes, like the formation of pits and pores. Through these pores, cellular components are released into the extracellular fluid, simply due to the osmotic difference. Within the cell, the integration of silver creates a low molecular weight region where the DNA then condenses. Having DNA in a condensed state inhibits the cell's replication proteins contact with the DNA. Thus the introduction of silver nanoparticles inhibits replication and is sufficient to cause the death of the cell. Further increasing their effect, when silver comes in contact with fluids, it tends to ionize which increases the nanoparticles' bactericidal activity. This has been correlated to the suppression of enzymes and inhibited expression of proteins that relate to the cell's ability to produce ATP.
Though delayed a year to reach its first flight, Gemini was able to take advantage of the USSR's two-year hiatus after Voskhod, which enabled the US to catch up and surpass the previous Soviet superiority in piloted spaceflight. Gemini had ten crewed missions between March 1965 and November 1966: Gemini 3, Gemini 4, Gemini 5, Gemini 6A, Gemini 7, Gemini 8, Gemini 9A, Gemini 10, Gemini 11, and Gemini 12; and accomplished the following:
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.